11 Jul 2019 10:38
AIM share code: SKIN
11 July 2019
Integumen PLC
("Integumen" or "Company")
Exercise of Warrants (update)
Further to the announcement headed "Exercise of Warrants" notified on 10 July 2019, the Company confirms that application has been made for the 803,572 ordinary shares referred to in that announcement to be admitted to trading on AIM, which is expected to be on or about 16 July 2019. These shares will rank pari passu with the ordinary shares of the Company in issue.
Integumen plc | Gerard Brandon, CEO
| +44 (0) 7340 055 648 |
SPARK Advisory Partners Limited (Nominated Adviser)
| Neil Baldwin/Vassil Kirtchev | +44 (0) 113 370 8974 |
Turner Pope Investments (TPI) Limited (Broker) | Andy Thacker | +44 (0) 20 3621 4120 |
About Integumen:
Integumen is a vertically integrated business, collaborating their Labskin technology platform with partners in artificial intelligence, clinical research, medical device and life science. These collaborators are building their own technology on top of the Labskin AI backbone. Labskin allows skin-care, health-care, pharmaceutical manufacturers and cosmetic companies to test their products on human-like skin in a real-world environment with full access to multiple state-of-the-art partner technologies.
The Company combines data analytics with access to therapeutic operational expertise and offers solutions to our clients, from regulatory approvals, right through to marketing fully tested ingredients that have been certified on our Laboratory grown living human tissue.